Background: Pertussis toxin (PTX) blocks GPCR signaling resulting in the inhibition of
U1 cells. 8 Furthermore, the in vivo intravenous administration of PTX has been shown to induce significant lymphocytosis in addition to a decrease in the number of SIV-infected cells 9 without any noted toxicity. These previous findings coupled by the ability of PTX to inhibit lymphoid cell recruitment prompted us to carry out the studies reported herein.
| MATERIALS AND METHODS

| Animals
Four adult female rhesus macaques (Macaca mulatta) of Indian origin were used for the studies reported herein. The animals were born 
| Pertussis toxin preparation and administration
Pertussis toxin in HEC gel form was prepared according to the protocol described by Moench et al 10 Briefly, the lyophilized form of pertussis toxin (Cat # 180, List Biological Laboratories, Inc., Campbell, CA,) was resuspended in 1.5 mL of sterile water. On day zero, 10 μg/kg of PTX was incorporated in 1 mL of HEC gel and administered intravaginally using a nasogastric PVC feeding tube.
This was followed immediately by the insertion of a sterile small glass tube (round end first) that was used to spread the gel along the vaginal vault. One hour following the first exposure of PTX, a second dose of 10 μg/kg of the toxin in 1 mL of HEC gel was similarly administered.
| Virus infection
Two hours after the last application of the PTX in HEC gel, each rhesus macaque was challenged by intravaginal exposure to 1 mL neat virus stock of SIV mac251 (100 000 TCID50 containing 720 ng of p27).
The virus stock of SIVmac251 was obtained courtesy of Dr. Nancy
Miller (NIAID, NIH). Data from the initial intravaginal titration studies showed that 1 mL of a 1/20 dilution of the stock virus (5000 TCID50 containing 36 ng of p27) was sufficient to infect 50% of monkeys via the IVAG route. The 1/20 dilution of the stock SIVmac251 dose was used in our previous studies to successfully infect female rhesus macaques via the IVAG route. 
| Sample collection
Blood was collected from anesthetized monkeys into EDTA collection tubes and plasma separated after centrifugation. Cervicovaginal lavage (CVL) was collected by irrigation of the vaginal vault with 2 mL of sterile DPBS, followed by aspiration from the posterior vaginal fornix.
| Plasma viral loads
Plasma viral loads were monitored in samples every week for 6 weeks, and every 2 weeks up to 10-15 weeks, using previously published protocols. Macaques were only considered infected when their plasma viral loads showed >1000 vRNA copies/mL at 2 consecutive weekly intervals. The threshold for the assay was 50 vRNA copies/ mL of plasma. 
| RESULTS
| Experimental design
The objective of this study was to generate preliminary data aimed at assessing the feasibility and efficacy of the vaginal application of PTX as a topical microbicide against SIV. As described in Figure 1 , following 2 baseline collections, PTX (10 μg/kg) was applied to the vaginal wall incorporated in HEC gel at 0 and at 1 hour followed 2 hours later by a single high-dose intravaginal challenge with SIVmac251 to a group of four adult rhesus macaques. None of the animals were treated with Depo-Provera. Infection was defined as plasma-positive viremia at two consecutive weeks. Macaques were bled weekly for 6 weeks, biweekly until 12 weeks thereafter to measure chemokines/ cytokines and plasma viral loads.
| Plasma viral loads
Two of the four female rhesus macaques exposed to PTX followed by challenge with SIVmac251 via the IVAG route showed readily detectable virus at week one that was confirmed by results of plasma viremia on samples collected on the second week post-challenge (see Unlike, plasma samples MIP-1 α levels were clearly up-regulated at week 1 and 2, but at later time points, the levels were similar to baselines values ( Figure 3B ).
| DISCUSSION
It is to be kept in mind that the present study was conducted to provide some preliminary data as to the feasibility of the use of PTX as an agent that could be utilized to test as a potential prevention strategy of HIV/SIV transmission. It is clear from the results of the study that a much larger cohort of animals is needed to derive meaningful data. More importantly, it is to be noted that the present study utilized a relatively high dose of highly pathogenic SIVmac251 (100 000 TCID50/dose) primarily because it is a well-known fact that intravaginal challenge studies require high doses and are notorious for resulting in resistance of animals to infection. Thus, we reason that a much lower dose in a repeated challenge model may be more optimal to provide meaningful data. The present study, however, does provide data on the feasibility of the approach and indicates that at the doses utilized it is probably safe as there were no recognized signs of toxicity associated with the procedure. Previously, it has been suggested that PTX has an effect on the innate immune system by inhibiting the early recruitment of neutrophils and macrophages, and has been shown to interfere with early chemokine production. It will be very interesting to test whether additional dose or repeated administration of PTX will lead to adverse effects on genital mucosa or helps to protect against SIV infection. This information will be very valuable to model the cohort of commercial sex workers (CSW) who are highly exposed to potential HIV infection 16 and whom we submit will theoretically utilize such gel applications on a regular basis to control HIV infection. Currently, it is unclear whether repeated administration of PTX is immunogenic leading to the production of anti-PTX antibodies and the potential of such antibodies to neutralize the anti-HIV effects of the PTX when applied locally and therefore will be intriguing to test these concepts in future studies. In this context, it is important to note that pertussis vaccine is routinely administered during childhood and is followed by booster immunization during adolescence, and thus, individuals could have such anti-PTX antibodies in their circulation that could neutralize the PTX when administered as a gel formulation. However, it is not clear whether such antibodies are present in CVL or locally within the vaginal mucosa. 17, 18 This should therefore be taken into consideration before deciding on any large-scale studies.
In conclusions, the results of this preliminary study provide a foundation for more extended studies aimed at the evaluation of PTX as a potential agent for inhibiting HIV/SIV transmission. In addition, this study warrants extensive large-scale animal studies involving lowdose IVAG challenge and repeated administration of PTX. 
ACKNOWLEDGMENTS
